News Column

Recent Studies by Y. Matsumura and Co-Authors Add New Data to Pre-Trial Research Findings (The Drug Discovery by NanoMedicine and its Clinical...

July 7, 2014



Recent Studies by Y. Matsumura and Co-Authors Add New Data to Pre-Trial Research Findings (The Drug Discovery by NanoMedicine and its Clinical Experience)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Clinical Trials and Studies have been published. According to news reporting originating from Kashiwa, Japan, by NewsRx editors, the research stated, "It is expected that the incidence of various adverse effects of anticancer agents maybe decreased owing to the reduced drug distribution in normal tissue. Anticancer agent incorporating nanoparticles including micelles and liposomes can evade non-specific capture by the reticuloendothelial system because the outer shell of the nanoparticles is covered with polyethylene glycol."

Our news editors obtained a quote from the research, "Consequently, the micellar and liposomal carrier can be delivered selectively to a tumor by utilizing the enhanced permeability and retention effect. Presently, several anticancer agent-incorporating nano-carrier systems are under preclinical and clinical evaluation. Several drug delivery system formulations have been approved worldwide. Regarding a pipeline of clinical development of anticancer agent incorporating micelle carrier system, several clinical trials are now underway not only in Japan but also in other countries. A Phase 3 trial of NK105, a paclitaxel incorporating micelle is now underway."

According to the news editors, the research concluded: "In this paper, preclinical and clinical studies of NK105, NC-6004, cisplatin incorporating micelle, NC-6300, epirubicin incorporating micelle and the concept of cancer stromal targeting therapy using nanoparticles and monoclonal antibodies against cancer related stromal components are reviewed."

For more information on this research see: The Drug Discovery by NanoMedicine and its Clinical Experience. Japanese Journal of Clinical Oncology, 2014;44(6):515-525. Japanese Journal of Clinical Oncology can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press - www.oup.com/; Japanese Journal of Clinical Oncology - jjco.oxfordjournals.org)

The news editors report that additional information may be obtained by contacting Y. Matsumura, Natl Canc Center Hosp East, Res Center Innovat Oncol, Div Dev Therapeut, Kashiwa, Chiba 2778577, Japan (see also Clinical Trials and Studies).

Keywords for this news article include: Asia, Japan, Kashiwa, Therapy, Nanoparticle, Nanotechnology, Pre-Trial Research, Emerging Technologies, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters